Navigation Links
Valeant Pharmaceuticals Announces License Of ACZONE® (dapsone) Gel 5% In Canada

MISSISSAUGA, Ontario, Feb. 8, 2011 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) today announced that its subsidiary, Biovail Laboratories International SRL (BLS), has entered into an agreement to license the Canadian rights to ACZONE® (dapsone) Gel 5%, a topical formulation of dapsone used in the treatment of acne vulgaris, from Allergan. Allergan will receive from BLS a CA$500,000 upfront payment to be followed by subsequent additional payments based on net sales.

"ACZONE® Gel is a strong addition to our Canadian business," said J. Michael Pearson, chief executive officer.  "This compound was originally approved in 2006 and never launched into the Canadian marketplace, providing Valeant Canada with a unique opportunity to strengthen and enhance our dermatology portfolio in Canada."

About ACZONE® Gel ACZONE® Gel is used to treat acne in patients 12 years of age and older. Acne is a skin condition characterized by the development of whiteheads, blackheads and other types of pimples. While acne can affect patients of any age, the condition is especially prevalent during adolescence.

Important Safety InformationACZONE® Gel is indicated for the topical treatment of acne vulgaris. ACZONE® Gel is not for oral, ophthalmic, or intravaginal use. ACZONE® Gel is contraindicated in patients who are hypersensitive to dapsone or to any ingredient in the formulation or component of the container.  Combination of ACZONE® Gel with trimethoprim/sulfamethoxazole (TMP/SMX) may increase the likelihood of hemolysis in patients with G6PD (glucose-6-phosphate dehydrogenase) deficiency.  The most common events reported from the clinical trials with ACZONE® Gel include oiliness/peeling, dryness, and erythema.  Serious adverse events reported in patients treated with ACZONE® Gel during clinical trials included but were not limited to severe pharyngitis, abdominal pain, severe vomiting, pancreatitis, suicide attempt, tonic clonic movements.

About Valeant Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of neurology, dermatology and branded generics.  More information about Valeant can be found at

FORWARD-LOOKING STATEMENTS This press release may contain forward-looking statements, including, but not limited to, statements regarding growth opportunities for Valeant's Canadian dermatology portfolio. Forward-looking statements may be identified by the use of the words "anticipates," "expects," "intends," "plans," "should," "could," "would," "may," "will," "believes," "estimates," "potential," or "continue" and variations or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, risks and uncertainties discussed in the company's most recent annual or quarterly report filed with the U.S. Securities and Exchange Commission, which factors are incorporated herein by reference.  Readers are cautioned not to place undue reliance on any of these forward-looking statements. Valeant undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this press release or to reflect actual outcomes.Contact:Laurie W. LittleValeant Pharmaceuticals 949-461-6002(Logo:


SOURCE Valeant Pharmaceuticals International, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Valeant Launches Senior Notes Offering
2. Valeant Pharmaceuticals to Acquire PharmaSwiss S.A.
3. Regulatory Update - GSK and Valeant Receive Positive Opinion in Europe From the CHMP for Trobalt (Retigabine)
4. Valeant Pharmaceuticals Appoints Philip W. Loberg as Interim CFO
5. Valeant Pharmaceuticals Announces Appointment of Robert A. Ingram and Resignation of William M. Wells as Chairman
6. Valeant Announces Pricing of Senior Notes
7. Valeant Declares Special Dividend and Plans to Create a Special Dividend Reinvestment Plan
8. Valeant Pharmaceuticals Reports 2010 Third Quarter Financial Results
9. Valeant Pharmaceuticals Announces That Alexza Pharmaceuticals Has Received a Complete Response Letter for AZ-004 (Staccato® Loxapine) Inhalation Aerosol NDA
10. Valeant Pharmaceuticals Announces Redemption and Defeasance of 7.625% Senior Notes Due 2020 and 8.375% Senior Notes Due 2016
11. Valeant and Biovail Announce Results of Special Meetings of Shareholders
Post Your Comments:
(Date:11/30/2015)... -- Kevin Smith has been appointed Chief Commercial Officer ... wireless monitoring of vital signs.  As CCO based ... Smith will be responsible for the development and ... also directly oversee partnering with US hospitals and ... the first early warning detection device to be ...
(Date:11/30/2015)... Nov. 30, 2015  The fee-for-service reimbursement ... U.S. medical imaging is on its way ... care payer-provider contracts are set to phase ... wake, alter provider-vendor relationships. The shift to ... forward new purchasing frameworks in the medical ...
(Date:11/30/2015)... SAN DIEGO , Nov. 30, 2015 ... ARNA ) today announced that the U.S. Food ... New Drug Application (NDA) for an extended release formulation ... offer patients a chronic weight management treatment in a ... currently approved as an adjunct to a reduced-calorie diet ...
Breaking Medicine Technology:
(Date:11/30/2015)... ... 30, 2015 , ... The Progressive Dental Institute ... 29 and 30, 2016. The course welcomes dental professionals and members of their ... how to better succeed in the modern dental marketplace. The course combines presentations ...
(Date:11/30/2015)... , ... November 30, 2015 , ... ... key disease-causing component of bacteria could be effective in fighting methicillin-resistant Staphylococcus aureus ... State University. , Their study showed that small molecule analogs that target the ...
(Date:11/30/2015)... NJ (PRWEB) , ... November 30, 2015 , ... Dr. ... With three office locations, patients can visit Dr. Margulies to experience the best available ... to hold the title of "NJ Top Dentist"! , Orthodontics is the branch of ...
(Date:11/30/2015)... ... November 30, 2015 , ... ”Dying Words: The AIDS Reporting ... on December 1, 2015, to coincide with World AIDS Day. The multi-media project will ... covered the AIDS epidemic as he was dying of the disease. , A collaborative ...
(Date:11/30/2015)... ... November 30, 2015 , ... According to RF Safe, the ... scientist at Consumer Reports as supporting a “A Call for Clarity” on cell ... The original Nov 2015 CR story titled, “Does Cell-Phone Radiation Cause Cancer?” ...
Breaking Medicine News(10 mins):